v3.26.1
Equity Incentive Plan (Tables)
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Schedule of Weighted Average Assumptions used for Stock Options

The Company granted stock options during the first quarter of 2026 and 2025. There were no stock option grants during the second quarter of 2026 or 2025. The following table presents the weighted-average assumptions used for stock options granted during the following periods:

  

   2026   2025 
  

Six Months Ended June 30,

 
   2026   2025 
Grant date fair value  $1.91   $11.59 
Risk-free interest rate   3.8%   4.7%
Dividend yield   0.00%   0.00%
Expected life in years   6.0    5.9 
Expected volatility   135%   110%
Schedule of Stock Based Compensation Expense

  

   2026   2025   2026   2025 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2026   2025   2026   2025 
Research and development  $3,991   $8,100   $18,303   $15,720 
Selling, general and administrative   37,789    31,134    66,755    60,702 
Total  $41,780   $39,234   $85,058   $76,422 
Schedule of Stock Option Activity

A summary of the Company’s stock option activity (inclusive of the Inducement Award) is as follows:

  

  

Number of

Options

Outstanding

  

Weighted-

Average

Exercise

Price

  

Weighted-

Average

Remaining

Contractual

Term (in

Years)

 
Balance at December 31, 2025   20,477   $25.27    8.9 
Options granted   147,000    2.09    - 
Options exercised   -    -    - 
Options forfeited   (3,066)   6.00    - 
Balance at June 30, 2026   164,411   $4.91    9.4 
                
Options exercisable at June 30, 2026   17,666   $18.73    8.7